Current and historical daily PE Ratio for IRLAB Therapeutics AB (
) from 2017 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. IRLAB Therapeutics AB stock (OSTO:IRLAB A) PE ratio as of Jun 20 2024 is 0.
More Details
IRLAB Therapeutics AB (OSTO:IRLAB A) PE Ratio (TTM) Chart
IRLAB Therapeutics AB (OSTO:IRLAB A) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1272
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| IRLAB Therapeutics AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-21 | At Loss | 2024-04-15 | At Loss |
| 2024-06-19 | At Loss | 2024-04-12 | At Loss |
| 2024-06-18 | At Loss | 2024-04-11 | At Loss |
| 2024-06-17 | At Loss | 2024-04-10 | At Loss |
| 2024-06-14 | At Loss | 2024-04-09 | At Loss |
| 2024-06-13 | At Loss | 2024-04-08 | At Loss |
| 2024-06-12 | At Loss | 2024-04-05 | At Loss |
| 2024-06-11 | At Loss | 2024-04-04 | At Loss |
| 2024-06-10 | At Loss | 2024-04-03 | At Loss |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-05 | At Loss | 2024-03-28 | At Loss |
| 2024-06-04 | At Loss | 2024-03-27 | At Loss |
| 2024-06-03 | At Loss | 2024-03-26 | At Loss |
| 2024-05-31 | At Loss | 2024-03-25 | At Loss |
| 2024-05-30 | At Loss | 2024-03-22 | At Loss |
| 2024-05-29 | At Loss | 2024-03-21 | At Loss |
| 2024-05-28 | At Loss | 2024-03-20 | At Loss |
| 2024-05-27 | At Loss | 2024-03-19 | At Loss |
| 2024-05-24 | At Loss | 2024-03-18 | At Loss |
| 2024-05-23 | At Loss | 2024-03-15 | At Loss |
| 2024-05-22 | At Loss | 2024-03-14 | At Loss |
| 2024-05-21 | At Loss | 2024-03-13 | At Loss |
| 2024-05-20 | At Loss | 2024-03-12 | At Loss |
| 2024-05-17 | At Loss | 2024-03-11 | At Loss |
| 2024-05-16 | At Loss | 2024-03-08 | At Loss |
| 2024-05-15 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
IRLAB Therapeutics AB (OSTO:IRLAB A) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
IRLAB Therapeutics AB
ISIN : SE0012675361
Share Class Description:
OSTO:IRLAB A: Class ACompare
Compare
Traded in other countries / regions
IRLAB A.Sweden6IRA.Germany IPO Date
2017-02-28Description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers